Literature DB >> 17367655

Intravenous repeated-dose toxicity study of ZnPcS2P2-based-photodynamic therapy in beagle dogs.

Wei Liu1, Naisheng Chen, Hongtao Jin, Jinling Huang, Jinfeng Wei, Jie Bao, Chenghe Li, Yan Liu, Xueyong Li, Aiping Wang.   

Abstract

The purpose of current study was to investigate the potential repeated dosed toxicity of ZnPcP(2)S(2)-based photodynamic therapy (ZnPc-PDT) in Beagle dogs. Twenty-four Beagle dogs were randomly allocated to four groups, in which they were administered ZnPcS(2)P(2) preparation intravenously at dosages of 0, 0.5, 1.5, and 4.5mg/kg body weight and then were irradiated with 670nm laser for 6min at subsequent 48 and 72h, once every four days for successively 10 times. There were no abnormal changes in clinical observations. After the administration most animals showed dysphoria and several had light edema on their faces. The results showed no mortality and no abnormity in ophthalmoscopy, electrocardiography, hematology, blood biochemistry and urinalysis, except that some statistical changes in specific indexes such as APTT in 1.5 and 4.5mg/kg groups, and these changes disappeared at the end of recovery. Histopathological examination showed hepatic spotty and lytic necrosis in Beagle dogs of 4.5mg/kg group, and at the end of recovery the damages alleviated. Additionally, some Kelly and Khaki granules presented in liver, spleen, lungs, kidneys, ovaries, lymph nodes, marrows and injection points. These drug pigmentations will provide valuable information about distribution of ZnPcP(2)S(2). Based on the results; the NOAEL was considered to be 1.5mg/kg and ZnPc-PDT appears to be a safety and promising approach in clinic.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17367655     DOI: 10.1016/j.yrtph.2006.06.006

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  4 in total

1.  Pentalysine beta-carbonylphthalocyanine zinc: an effective tumor-targeting photosensitizer for photodynamic therapy.

Authors:  Zhuo Chen; Shanyong Zhou; Jincan Chen; Yicai Deng; Zhipu Luo; Hongwei Chen; Michael R Hamblin; Mingdong Huang
Journal:  ChemMedChem       Date:  2010-06-07       Impact factor: 3.466

2.  Use of a novel sonosensitizer in sonodynamic therapy of U251 glioma cells in vitro.

Authors:  Zhiqiang Chen; Jianhua Li; Xueming Song; Zhi Wang; Wu Yue
Journal:  Exp Ther Med       Date:  2011-11-25       Impact factor: 2.447

3.  A Tumor-pH-Responsive Supramolecular Photosensitizer for Activatable Photodynamic Therapy with Minimal In Vivo Skin Phototoxicity.

Authors:  Xingshu Li; Bi-Yuan Zheng; Mei-Rong Ke; Yongfan Zhang; Jian-Dong Huang; Juyoung Yoon
Journal:  Theranostics       Date:  2017-07-07       Impact factor: 11.556

4.  A novel tumor targeting drug carrier for optical imaging and therapy.

Authors:  Rui Li; Ke Zheng; Ping Hu; Zhuo Chen; Shanyong Zhou; Jincan Chen; Cai Yuan; Song Chen; Wei Zheng; En Ma; Fengling Zhang; Jinping Xue; Xueyuan Chen; Mingdong Huang
Journal:  Theranostics       Date:  2014-03-24       Impact factor: 11.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.